Figure 2.
Barriers to allo-HCT in patients for whom it was recommended for but did not subsequently undergo transplant. AML; acute myeloid leukemia. ALL; acute lymphoblastic leukemia (both B-cell ALL and T-cell ALL); MPAL, mixed phenotypic acute leukemia. * It is possible that patients transferred to another center (n = 10 of overall population) may have subsequently received an allo-HCT at an outside institution.